The Survivin Suppressant YM155 Potentiates Chemosensitivity to Gemcitabine in the Human Pancreatic Cancer Cell Line MiaPaCa-2
Anticancer Research, 05/17/2012Yoon DH et al.
YM155 potentiates chemosensitivity to gemcitabine in pancreatic cancer cells by suppressing the induction of survivin. Combination treatment with gemcitabine and YM155 may be a potential therapeutic strategy for the treatment of pancreatic cancer that warrants further clinical investigation.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.